Page last updated: 2024-12-05

hexylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hexylamine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-hexanamine : A 6-carbon primary aliphatic amine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8102
CHEMBL ID1320720
CHEBI ID5712
SCHEMBL ID15939
MeSH IDM0051415

Synonyms (61)

Synonym
n-hexylamine
wln: z6
1-hexylamine
nsc2590
1-aminohexane
nsc-2590
mono-n-hexylamine
nsc 2590
brn 1731298
einecs 203-851-8
ai3-16554
ent 16554
inchi=1/c6h15n/c1-2-3-4-5-6-7/h2-7h2,1h
hexan-1-amine
NCGC00091816-01
111-26-2
C08306
hexylamine
1-hexanamine
hexylamine, 99%
H0134
hexanamine
STK802350
AKOS000119866
NCGC00091816-02
hexyl-amine
cas-111-26-2
dtxcid801930
dtxsid3021930 ,
NCGC00257590-01
tox21_200036
BBL011106
CHEBI:5712 ,
4-04-00-00709 (beilstein handbook reference)
hsdb 8444
ci4e002zv8 ,
unii-ci4e002zv8
ec 203-851-8
FT-0607346
hexyl amine
BP-30167
SCHEMBL15939
fema no. 4243
hexylamine [fhfi]
n-hexyl amine
n-n-hexylamine
hexane-1-amine
pentylmethanamine
n-c6h13nh2
CHEMBL1320720
mfcd00008240
J-002548
F2191-0288
hexylamine, analytical standard
hexylamine, purum, >=98.0% (gc)
hexyl amine-1
Q426238
VS-02837
AMY21942
EN300-19756
BP-31178

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" After 24 h treatment with amine, the MAO activity of cultured skin fibroblasts was elevated in a dose-response manner."( Increased activity of monoamine oxidase by epoxy resin hardeners.
Yano, E, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
primary aliphatic amine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency61.64483.189029.884159.4836AID1224846
GLI family zinc finger 3Homo sapiens (human)Potency52.20380.000714.592883.7951AID1259369; AID1259392
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.00450.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency59.97490.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.02750.000229.305416,493.5996AID743075
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency58.19650.057821.109761.2679AID1159528
heat shock protein beta-1Homo sapiens (human)Potency57.13250.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.49150.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (26.92)18.7374
1990's7 (13.46)18.2507
2000's14 (26.92)29.6817
2010's16 (30.77)24.3611
2020's1 (1.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.28 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index107.94 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]